TAREG
As listed in the register: TAREG 160 mg, comprimé pelliculé
160 mg · comprimé pelliculé
- Prescription only
- Active substance
- Valsartan
- Made by
- NOVARTIS PHARMA
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (valsartan). It describes the substance, not this Bulgarian product — its uses and doses can differ.
Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).
Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.
In vitro metabolism studies involving recombinant CYP 450 enzymes indicated that the CYP 2C9 isoenzyme is responsible for the formation of valeryl-4-hydroxy valsartan.
Effect of Food With the tablet, food decreases the exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C max ) by about 50%.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-25
Safety of the active substance
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (valsartan). It describes the substance, not this Bulgarian product — its uses and doses can differ.
WARNING: FETAL TOXICITY.
- Do not use in patients with known hypersensitivity to any component.
- Do not coadminister aliskiren with valsartan tablets in patients with diabetes [see Drug Interactions ( 7.3 )].
- Known hypersensitivity to any component.
The most common reasons for discontinuation of therapy with valsartan were headache and dizziness.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States31 matching products
Bulgaria10 matching products
- Diovan 160 mg · film-coated tablets2 makers
- Sarteg 160 mg film-coated tablets · film coated tablet
- Suvartar 160 mg · film - coated tablets
- Valdipin 160 mg · film - coated tablets
- Valsacor 160 mg · film - coated tablets
- Valsarcon 160 mg · film - coated tablets
- Valsavil 160 mg · film - coated tablets
- Valtensin 160 mg · film-coated tablets
Canada9 matching products
Netherlands11 matching products
- Diovan 160 160 mg · filmomhulde tablet
- Exsartz 160 mg 160 mg · filmomhulde tablet
- Vagrecor 160 mg filmomhulde tabletten 160 mg · filmomhulde tablet
- Valsartan 160 mg tabletten PCH 160 mg · filmomhulde tablet
- Valsartan Aurobindo 160 mg filmomhulde tabletten 160 mg · filmomhulde tablet
- Valsartan CF 160 mg 160 mg · filmomhulde tablet
- Valsartan Jubilant 160 mg 160 mg · filmomhulde tablet
- Valsartan Krka 160 mg filmomhulde tabletten 160 mg · filmomhulde tablet
Details
| Made by | NOVARTIS PHARMA |
|---|---|
| Active substance | Valsartan |
| Strength | 160 mg |
| Form | comprimé pelliculé |
| Route | orale |
| Dispensing (as stated by the register) | liste I |
| Marketed | Yes, according to the register |
| Authorisation procedure | Procédure de reconnaissance mutuelle |
| Name in the register | TAREG 160 mg, comprimé pelliculé |
| Packs | plaquette(s) PVC PVDC aluminium de 30 comprimé(s) · plaquette(s) PVC PVDC aluminium de 90 comprimé(s) |
| CIS | 61823653 |
| CIP13 | 3400938155242 |
| CIP13 | 3400938155532 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).
Other strengths and forms
4 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.